Navigation Links
Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
Date:11/7/2011

ation with ChronTech Pharma AB and Transgene S.A. to test the immunogenicity of a DNA/electroporation prime - MVA boost approach against HCV by combining two promising, previously studied clinical candidates. A Phase I clinical study is anticipated to start in Q4 2011.

About Inovio Pharmaceuticals, Inc. Inovio is developing its revolutionary synthetic consensus immunogen technologies to extend the profound medical benefits of the 20th century's immune-system-stimulating vaccines by preventing and treating today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery method, have been shown in humans to be safe and generate best-in-class immune responses. Inovio's clinical programs include Phase II studies for cervical dysplasia/cancer, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this re
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  Amgen (NASDAQ: AMGN ) today announced ... director of Warburg Pincus LLC, to the Amgen Board of ... Fred Hassan and the deep, global experience he brings ... Robert A. Bradway , chairman and chief executive officer of Amgen. ... serve Amgen well." Mr. Hassan has been Partner ...
(Date:7/30/2015)... LAKE, N.J. , July 30, 2015 ... simultaneously in the United States , ... the FDA, EMA and MHLW, respectively) for eribulin, for ... (STS) who have received prior chemotherapy for advanced or ... based on data from a pivotal global Phase 3 ...
(Date:7/30/2015)... 2015 P&S Market ... market overview, trends, DRO analysis, market segmentation, ... developments, competitive scenario and top competitor profiles ... Market Development and Demand Forecast to 2020  ... Explore more about global biosensors ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
... Aug. 30, 2011 Luminex Corporation (Nasdaq: ... two upcoming investment conferences, the Morgan Stanley Global Healthcare ... scheduled to take place in New York City. ... Patrick J. Balthrop, president and chief executive officer, will ...
... REDWOOD CITY, Calif., Aug. 30, 2011 Pearl ... randomized, double-blind, Phase 2b, dose-ranging study of its ... a long-acting beta-2 agonist (LABA) compared to placebo ... All doses of FF MDI tested produced highly ...
Cached Medicine Technology:Luminex Corporation to Present at Upcoming Investment Conferences In September 2Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI 2Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI 3
(Date:8/1/2015)... ... ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, was named one ... Federation, the largest retail trade association in the world, for her “advocacy and engagement” ... named as such. According to the NRF’s website, Retail Champions are “Main Street business ...
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
(Date:8/1/2015)... ... ... Lume Wellness creators Alex, Robert, and Sam have announced update 3.0.1 to this ... The app is designed to track various metrics of wellness, including physical activity, diet, ... and use this information for positive behavior modification. Lume Wellness keeps track of both ...
(Date:8/1/2015)... ... 2015 , ... “ reTXT ” was featured on NewsWatch as part of ... the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and ... edit and delete any message including ones already sent. , While text messaging has ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... High Times magazine. What are the STASH awards? The Significant Technological Achievements ... by the cannabis-cultivation community as well as tried-and-true products that have stood the ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2
... tablets such as pain killers are packaged today in ... some form of desiccant to protect the contents against ... the contents from rattling around. , However, such caps ... two hands to manipulate. Customers and,suppliers of vitamin pills ...
... an army of plant viruses to their cause, materials ... (NIST) have identified a small biomolecule that binds specifically ... bodythe calcium compound that is the basic building block ... the new molecule can be a highly discriminating probe ...
... American Tradition -- What,s the Problem?, ... Seniors Ask, WASHINGTON, ... the sight of seniors attending a,seminar about Medicare Advantage-Part D, asking questions, and ... some federal regulators,get their way., A proposed prohibition on free meals is ...
... ... Troops, BOSTON, July ... the most underserved and,at-risk groups in our country, today announced the launch ... those soldiers,who have been wounded in conflict in the Middle East and ...
... Hot Water & Healthy Living, reviews scientific findings about warm-water ... ... For those who have,wondered how warm water makes them feel so good, ... Swimming Pool Foundation,(NSPF), "Hot Water & Healthy Living" provides a thorough review ...
... ... Care, BREA, ... owners are recalculating their,household budgets. The average pet owner typically budgets for ... as,preventive health checks and vaccinations. However, most assume that their,pet,s youth or ...
Cached Medicine News:Health News:Integrated tube cap design simplifies access to medication 2Health News:Toothpick: New molecular tag IDs bone and tooth minerals 2Health News:Proposed Medicare Regulations Threaten to End Millions of Free Meals Offered to Seniors During Education Seminars 2Health News:Purple Dog Tag Launches; Provides Hope and Healing to Thousands of US Servicemen & Veterans 2Health News:New Book Reveals Warm Water Benefits for Heart, Lungs and Mind 2Health News:Veterinary Pet Insurance Reports Pet Emergencies a Costly Reality 2Health News:Veterinary Pet Insurance Reports Pet Emergencies a Costly Reality 3Health News:Veterinary Pet Insurance Reports Pet Emergencies a Costly Reality 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: